WELCOME!
to IMGT/mAb-DB

THE
INTERNATIONAL
IMMUNOGENETICS
INFORMATION SYSTEM®

Introduction

IMGT/mAb-DB is part of IMGT®, the international ImMunoGeneTics information system®, the high-quality integrated information system specialized in immunoglobulins (IG), T cell receptors (TR), major histocompatibility complex (MHC) of human and other vertebrates species, immunoglobulin superfamily (IgSF), MHC superfamily (MhcSF) and related proteins of the immune system (RPI) of vertebrates and invertebrates species, created in 1989 by Marie-Paule Lefranc (Laboratoire d'ImmunoGénétique Moléculaire, LIGM, Université Montpellier 2 and CNRS) and on the Web since July 1995. IMGT/mAb-DB is the IMGT® monoclonal antibodies (mAb) database.

IMGT/mAb-DB provides a unique expertised resource on monoclonal antibodies with clinical indications.

In 2008, amino acid sequences of monoclonal antibodies (IG, mAb) and fusion proteins for immune applications (FPIA) from INN/WHO were entered in IMGT/2Dstructure-DB, a section of IMGT/3Dstructure-DB.

IMGT/mAb-DB Query page

The IMGT/mAb-DB Query page allows five types of search Search by. It also allows to select fields to be displayed in the results Displayed Fields.

IMGT/mAb-DB five types of search

Section 1

Allows to query IMGT/mAb-DB by:

• IMGT/mAb-DB ID which has been defined in order to identify the monoclonal antibodies by numeric code.

Section 2

Allows to query IMGT/mAb-DB by:

• INN (International Nonproprietary Name) provided by WHO/INN (World Health Organization).
  The search by INN is case insensitive . A selection on INN is also possible in a drop-down list.
• INN number
• INN proposed list as published by WHO/INN.
  • 'and before' and 'and after': allows a search of mAb published before a proposed (or recommended) list.
• INN recommended list as published by WHO/INN.
• Common name includes name found in the literature. The search by Common name is case insensitive.
• Proprietary name includes antibody registered trademark, usually identified by symbol ™ (not yet registered) and ® (registered). The search by Proprietary name is case insensitive.

Section 3

Allows to query IMGT/mAb-DB by:

• IMGT receptor type includes
  • IG or antibody complete or partial (Fab, Fab', scFv). An IG (or antibody) is usually designated with the suffix 'mab' in INN if they contains at least one variable domain (for example VH).
    • IG class or subclass for complete IG
    • IG format for fragments or constructs
  • FPIA (fusion proteins for immune application) result generally from the fusion of a protein (2 molecules) with the Fc of an IG ('(protein)2:Fc' format). They usualy designated with the suffix '-cept' in INN.
    • FPIA chain identification
  • RPI (Related proteins of the immune system) comprise the proteins of the immunoglobulin superfamily (IgSF) other than IG and TR, and the proteins of the major histocompatibility superfamily (MhSF) other than MHC, which are involved in the immune response. They usualy designated with the suffix '-cept' in INN.
    • RPI chain identification
  • any includes entries with IMGT receptor type as : IG (complete and/or fragments IG) and/or FPIA and/or RPI
  • noneincludes entries without IMGT receptor type. If the button "none" is checked, a drop-down lists (for IG, FPIA and RPI) are reset.

• Species
  • Murine: A murine antibody is one of which both chain types are of mouse origin.
    A murine antibody is identified by the pre-stem -o- in its INN.
  • Rat: A rat antibody is one of which both chain types are of rat origin.
    A rat antibody is identified by the pre-stem -a- in its INN.
  • Chimeric: A chimeric antibody is one of which both chain types are chimeric as a result of antibody engineering. A chimeric chain is a chain that contains a foreign variable domain (V-D-J-REGION) (originating from one species other than human, or synthetic) linked to a constant region (C-REGION) of human origin.
    A chimeric antibody is identified by the pre-stem -xi- in its INN.
  • Humanized: A humanized antibody is one of which both chain types are humanized as a result of antibody engineering. A humanized chain is a chain in which the complementarity determining regions (CDR) of the variable domains are foreign (originating from one species other than human, or synthetic) whereas the remaining chain is of human origin. By extension an antibody is described as humanized if more recent protocoles were used for the humanization.
    A humanized antibody is identified by the pre-stem -zu- in its INN.
  • Human: A human antibody is one of which both chain types, and the J chain in the case of polymeric antibodies, are of human origin.
    A human antibody is identified by the pre-stem -u- in its INN. Note that, in the case of polymeric antibodies, the INN is only based on the immunoglobulin chain origin.
  • Hybrid: A hybrid antibody is one in which one-half of the antibody (one heavy chain and one light chain) is from one species origin whereas the other half is from another species origin.
    An hybrid antibody is identified by a INN pre-stem made of each species pre-stem separated by the letter 'x' in the INN. For example, a rat-murine hybrid antibody is identified by the pre-stem -axo-.

• Radiolabelled/Conjugated Monoclonals antibodies can be used:
  • Conjugated: with another molecule (toxin, antibiotic, chelator, enzyme, ...)
  • Radiolabelled: with an isotope, directly or via a chelator.

• Entries in IMGT/2Dstructure-DB allows to retrieve mAb and FPIA that have an entry in IMGT/2Dstructure-DB.
• Entries in IMGT/3Dstructure-DB allows to retrieve mAb and FPIA that have an entry in IMGT/3Dstructure-DB.
• Origin clone species: allows the selection on mAb clones of a single parent cell.
• Origin clone name: the search by clone is case insensitive.

Section 4

Allows to query IMGT/mAb-DB by:

• Specificity target name: A bispecific antibody is an antibody with two different variable domain binding sites (Fv), each binding to a different antigen. By keeping the "shift" key pressed, it's possible to select several specificity.
• Specificity target origin

Section 5

Allows to query IMGT/mAb-DB by:

• Clinical indication
• Development status:
  • Phase I: safety testing and pharmaceutical profiling in humans. In Phase I clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
  • Phase II: effectiveness in humans (dose-ranging studies in target population). In Phase II clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
  • Phase III: extensive clinical trial in humans (late-stage clinical trials in humans). In Phase III studies, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
  • Phase M: on the market.
  • Phase IV: trials complete; regulatory application filed. In Phase IV studies, the post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.

  These phases are defined by the FDA (Food and Drug Administration) in the Code of Federal Regulations.

  • "Orphan" status: In the U.S., the designation "orphan" status applies to a disease that affects fewer than 200,000 people. In the E.U., the designation "orphan" status defines drugs for rare conditions that affect not more than five in 10,000 people.
• Regulatory agency
  • AMM: Autorisation de mise sur le marché (Market authorization).
  • EC: European Commission.
  • EMA: European Medicines Agency for the Evaluation of Medical Products.
  • FDA: Food and Drug Administration. Antibodies and FPIA receiving approval by FDA but subsequently withdrawn from the market are not included in the result list.
  • REMS: Risk Evaluation and Mitigation Strategy.The FDA Amendments Act of 2007 gave FDA the authority to require a REMS from Antibodies and FPIA.
  • NCI: National Cancer Institute.
  • NCT: List of clinical trials.
  • NDA: New Drug Application.
  • sBLA: Supplemental Biologics License Application.
  • A query on Regulatory agency, without other fields, will all now products approved (not included the withdrawn ones).
• Year
• Company: propose a search on mAb creation and engineering company. Companies for one clinical indication are classed in a group and separated by "/". The search is case insensitive.
• Expression system: the expression system includes vectors that contains the entire human genomic constant region of a immunoglobulin heavy and/or light chain and is adaptable for insertion, without mutagenesis, of a nonhuman antibody variable region. The resulting expression vector includes the entire human genomic constant region and the entire nonhuman variable region lacking tissue specific promoter and/or enhancer regions normally associated with genomic DNA. The search is case insensitive.
• Application includes diagnostic and therapeutic.
• Clinical domain includes hematology, oncology, immunology, ophtalmology, pulmonary, radioimmunoscintigraphy, respiratory diseases and hereditary inflammatory diseases

IMGT/mAb-DB displayed fields

Allows to select fields to be displayed in the result.

IMGT/mAb-DB other definitions

• Immunotoxin: IG or FPIA linked with a toxin. Immunotoxins can be queried in Section 3 'Conjugated'. Examples of toxins in IMGT/mAb-DB: Pseudomonas aeruginosa exotoxin A or Staphyloccocus aureus enterotoxin A.
• Immunoadhesin: FPIA constituted of binding domain(s) (usually from a receptor, ligand, or cell-adhesion molecule) linked to immunoglobulin constant domains (Fc regions). An immunoadhesin is identified by the suffix -cept in its INN. Immunoadhesins can be queried in Section 2 'INN name' using 'cept'.
• Immunoconjugate: IG FPIA conjugated with another molecule (toxin, antibiotic, chelator, enzyme…). Immunoconjugate can be queried in Section 3 'Conjugated'.
• Original applications are generally submitted for new products or for new uses of food and color additives or for new food labeling claims.
  • IND: Investigational new drug application --for drugs and biologics.
  • NDA: New drug application --human drug.
  • PLA: Product license application --biologics.
  • ELA: Establishment license application --biologics.
  • BLA: Biologics license application --combines PLA and ELA for biologics.
  • PMA: Premarket application --medical device.
  • NADA: New animal drug application.

IMGT/mAb-DB Results

The result presentation depends on the displayed fields chose at the IMGT/mAb-DB Query page. On top of each result page, the query are recalled and the number of results is shown. Each displayed field corresponds to a title of column in result table.

At the bottom of every page, the references, notes and citations of every entry are available.

IMGT/mAb-DB Card

To get access to the IMGT/mAb-DB card, click in the IMGT/mAb-DB result page on the IMGT/mAb-DB Id (first column on the result).

Created:

03/04/2009

Database development:

Yan Wu, Patrice Duroux and Claire Poiron

Database scientific officer:

Marie-Paule Lefranc

• IMGT Home page
• IMGT Repertoire (IG and TR)
• IMGT Repertoire (MHC)
• IMGT Repertoire (RPI)
• IMGT Index
• IMGT Scientific chart
• IMGT Education

Software material and data coming from IMGT server may be used for academic research only, provided that it is referred to IMGT®, and cited as "IMGT®, the international ImMunoGeneTics information system® http://www.imgt.org (founder and director: Marie-Paule Lefranc, Montpellier, France)." References to cite: Lefranc, M.-P. et al., Nucleic Acids Research, 27, 209-212 (1999) Cover of NAR; Ruiz, M. et al., Nucleic Acids Research, 28, 219-221 (2000); Lefranc, M.-P., Nucleic Acids Research, 29, 207-209 (2001); Lefranc, M.-P., Nucleic Acids Res., 31, 307-310 (2003); Lefranc, M.-P. et al., In Silico Biol., 5, 0006 (2004) [Epub], 5, 45-60 (2005); Lefranc, M.-P. et al., Nucleic Acids Res., 33, D593-D597 (2005) Full text; Lefranc, M.-P. et al., Nucleic Acids Research 2009 37: D1006-D1012; doi:10.1093/nar/gkn838 Full text.
For any other use please contact Marie-Paule Lefranc Marie-Paule.Lefranc@igh.cnrs.fr.

        

IMGT founder and director:

Marie-Paule Lefranc Marie-Paule.Lefranc@igh.cnrs.fr

Bioinformatics manager:

Véronique Giudicelli Veronique.Giudicelli@igh.cnrs.fr

Computer manager:

Patrice Duroux Patrice.Duroux@igh.cnrs.fr

Webmaster:

Chantal Ginestoux Chantal.Ginestoux@igh.cnrs.fr

• Citing IMGT
• Warranty disclaimer and copyright notice
• Privacy policy and advertisement policy

© Copyright 1995-2012 IMGT®, the international ImMunoGeneTics information system®